




RealRate

MEDICINAL PRODUCTS & SUBSTANCES 2022

Intellia Therapeutics Inc. Rank 25 of 50



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



RealRate

MEDICINAL PRODUCTS & SUBSTANCES 2022

Intellia Therapeutics Inc. Rank 25 of 50



The relative strengths and weaknesses of Intellia Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Intellia Therapeutics Inc. compared to the market average is the variable Assets, increasing the Economic Capital Ratio by 228% points. The greatest weakness of Intellia Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 101% points.

The company's Economic Capital Ratio, given in the ranking table, is 27%, being 256% points above the market average of -229%.

Input Variable	Value in 1000 USD
Assets Hidden Reserves	0
Assets, Current	769,303
Assets, Non-Current	474,635
General and Administrative Expense	71,096
Goodwill	0
Liabilities Hidden Reserves	0
Liabilities, Current	125,833
Liabilities, Non-Current	0
Other Assets	29,558
Other Compr. Net Income	-2,633
Other Expenses	0
Other Liabilities	0
Other Net Income	42
Property, Plant and Equipment, Net	20,968
Research and Development	229,807
Revenues	33,053

Output Variable	Value in 1000 USD
Liabilities	125,833
Assets	1,294,464
Expenses	300,903
Market Value Liabilities	125,833
Market Value Assets	1,294,464
Stockholders Equity	1,168,631
Net Income	-267,808
Comprehensive Net Income	-269,124
Economic Capital Ratio	27%



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai